Page 1242 - Basic _ Clinical Pharmacology ( PDFDrive )

1228 Index

Necitumumab, 968, 992 depolarizing cotransmitters in cholinergic and
Nedocromil, 281 mechanism of action, 478f–479f, adrenergic nerves in, 97–98
allergic rhinoconjunctivitis treated with, 479t, 480 endocannabinoids, 377t, 379–380
356, 362t pharmacokinetics of, 477–478, 478t monoamine
asthma treated with, 355–356, 360 disease and aging on neuromuscular dopamine, 374f, 376t, 378
Nefazodone, 538, 540t, 542t, 546t, 547, response, 484 histamine, 376t, 379
550t. See also 5-HT receptor drug interactions, 483 5-hydroxytryptamine, 374f, 376t, 379
modulators fundamentals of, 474 norepinephrine, 374f, 376t, 378–379
Negative allosteric modulators, 24 history of, 474 neuropeptides, 379
Nelfinavir, 872t, 881 hyperkalemia, 483 nitric oxide, 380
Neoadjuvant chemotherapy, 949–950 intragastric pressure increase, 483 opioid peptides, 377t
Neomycin intraocular pressure increase, 483 orexins, 377t, 379
description of, 831–832, 833t mechanism of action of, 478f–479f, purine, 380
topical dermatologic, 1071 478–480 tachykinins, 377t
Neonicotinoids, 120 muscle pain, 483 Neurotransmitter uptake carriers, 95b
Neostigmine, 119, 122t neuromuscular transmission assessment, Neurotrophic hypothesis, for depression,
neuromuscular blockade reversal using, 479f, 480–481 533f, 533–534
483–484 nondepolarizing Neutral antagonism, 6
prokinetic activity of, 1097 mechanism of action, 475f, 478f, Neutropenia
structure of, 115, 116f 478–479, 479f, 479t cancer chemotherapy-induced, G-CSF
Neovascular age-related macular pharmacokinetics of, 476–477, 478t for, 603, 603f, 606t
degeneration, 1065 normal neuromuscular function and, description of, 592
Nephrogenic diabetes insipidus 474–475, 475f Nevirapine, 872t, 878
ADH antagonists as cause of, 268–269 pharmacokinetics of, 476–477 New Drug Application (NDA), 17
lithium as cause of, 527 preparations available, 490t New drug development, 11, 12f
Nephrolithiasis, diuretics for, 271–272 reversal of nondepolarizing blockade in, Niacin
Nephron, 256t 483 with bile-acid binding resins, 639
Nephrotic syndrome, 788 skeletal muscle paralysis, 480 dyslipidemia treated with, 639t
Neprilysin, 309 uses of, 484–485 with ezetimibe, 639
Neprilysin inhibitors, 225t, 312 Neuromuscular function, 474–475, 475f with reductase inhibitors, 639
Nernst equation, 229 Neuronal systems, 373–374, 374f Niaspan, 636
Nesiritide (BNP), 310. See also Natriuretic Neurons, 368, 368f Nicardipine
peptides local circuit, 373, 373f angina pectoris treated with, 202–206,
heart failure treated with, 220, 225t relay (projection), 373, 373f 203t, 210t
on kidney, 259 Neuropathy target esterase (NTE), 1011 hypertension treated with, 187
on vasoactive peptides, 317t Neuropeptides, CNS, 379 Niclosamide, 939t, 943
Netilmicin, 827f, 831 Neuropeptide Y antagonists, 318t Nicorandil, 202
Neural tube defects, folic acid supplements Neuropeptide Y (NPY), 92t, 315–316 Nicotine, 122t
and, 599b Neurotensin, 314 abuse of, 577t
Neurocysticercosis. See also Antihelminthics Neurotensin agonists, 317t analgesic uses of, 560b
albendazole for, 939t, 940 Neurotensin antagonists, 318t ionotropic receptors in, 583–584
praziquantel for, 944–945 Neurotransmitter pathways, diffuse brain, mechanism of action of, 583–584
Neuroglia, 368, 368f 373–374, 374f in pesticides, 1012
Neurohypophysis, 667, 668f Neurotransmitter receptors, in central prevalence of addiction to, 583
Neurokinin A, 313 nervous system, 369f, 369–370 structure of, 109, 110f
Neurokinin B, 313 Neurotransmitters, 90f, 93–98, 375–380 toxicity, 120–121
Neurokinin receptor antagonists, 1105 acetylcholine, 374f, 376t, 378 treatment for, 584, 588t
Neuroleptanesthesia, 519 amino acid, 375–378 Nicotinic acetylcholine receptor (nAChR)
Neuroleptic malignant syndrome (NMS), GABA and glycine, 376t, 378 description of, 475, 475f
288b, 288t glutamate, 375, 376t, 377f mechanism of action of, 29f, 29–30
antipsychotics as cause of, 523 autonomic Nicotinic (N) receptor
dyskinesia in, 506 adrenergic transmission in, 95–97, agonists of
Neuromedin N, 314 96f–97f direct-acting, 122t
Neuromuscular blocking drugs, 474–475, cholinergic and noradrenergic fibers partial, in nicotine abuse, 584, 588t
488t–489t in, 90f, 93 description of, 98, 99t, 114
cardiovascular effects, 481–482 cholinergic transmission in, 93–95, subtypes and characteristics of, 90f, 107,
chemistry of, 476, 476f, 477f 94f 108f, 108t
clinical pharmacology of, 480–485 cotransmitters in, 93 Nicotinic signaling, 110–112, 111f